2 September 2010

Dart Group

HOLD

07/01/2005

Last November, aviation services and distribution group Dart pleased investors with strong half time numbers to 30 September in some pretty tough markets. Profits, pre-tax and goodwill, spiked up from £7.4m to £11.1m on substantially higher turnover of £140.4m (£119.7m), and shareholders enjoyed a 10% dividend uplift to over 2p a share. During the first half, Dart's capital expenditure was some £23m, mainly pertaining to the purchase of Boeing 737-300 aircraft for its aviation services division. This part of the business, which delivered £89m of first half sales, includes freight forwarder Benair Freight International and Channel Express (Air Services), which operates contract charter passenger and freight air services. Channel Express also runs budget services from the North and Northern Ireland under the trading name Jet2.com. Dart's other division is the distribution one - Fowler Welch-Coolchain. It distributes fresh produce and horticulture products for supermarkets and their suppliers, and despite facing tricky pricing issues, management is optimistic about the division's 'future profitable growth'. Admittedly, Dart is a seasonal play, since the lauded Jet2.com turns in profits over the summer and losses in the weaker winter months. Yet last year to March, pre-tax profits (stripping out goodwill) edged up from £7.9m to £9m. And in an encouraging September update, Dart predicted pre-tax profits for the year to March 2005 would be 'materially' ahead of market expectations. Well worth holding.

Sector: General Industrials

Companies: Dart

Market cap: £129m

PE Forecast: n/a

Share price: 374p

Subscribe today


More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.

Subscribe today and save 50%

VCT Report 2010

VCT Report 2010 uncovers the money available

for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted

company.

Order VCT Report 2010 today using this online form

Cash Shells Directory 2010

A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.

Coverage of AIM, techMARK and PLUS Markets

Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.

Take control of your investments

A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.

The Financial Times Guide to Personal Tax

is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.

The AIM Guide Spring 2010

The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).

A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!

Share recommendations and small-cap stock picks

Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.

Popular Recommendations

Latest Recommendations

Delcam 01/09/2010

Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.

Antisoma 01/09/2010

Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.

GW Pharmaceuticals 31/08/2010

GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.

More Recommendations

Sectors

Vitesse Media Events